| MeSH term | MeSH ID | Detail |
|---|---|---|
| Inflammation | D007249 | 119 associated lipids |
| Diabetes Mellitus, Type 1 | D003922 | 56 associated lipids |
| Diabetes Mellitus, Type 2 | D003924 | 87 associated lipids |
| Body Weight | D001835 | 333 associated lipids |
| Cardiovascular Diseases | D002318 | 24 associated lipids |
| Tibial Fractures | D013978 | 4 associated lipids |
| Thrombosis | D013927 | 49 associated lipids |
| Endometriosis | D004715 | 29 associated lipids |
| Liver Cirrhosis | D008103 | 67 associated lipids |
| Cerebral Hemorrhage | D002543 | 13 associated lipids |
2,3-dinor, 6-keto-PGF1alpha
2,3-dinor, 6-keto-pgf1alpha is a lipid of Fatty Acyls (FA) class.
Cross Reference
There are no associated biomedical information in the current reference collection.
Current reference collection contains 782 references associated with 2,3-dinor, 6-keto-PGF1alpha in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.
Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.
Here are additional resources we collected from PubChem and MeSH for 2,3-dinor, 6-keto-PGF1alpha
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with 2,3-dinor, 6-keto-PGF1alpha
NCBI Entrez Crosslinks
All references with 2,3-dinor, 6-keto-PGF1alpha
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| pmid: | ||||
| Catella-Lawson F et al. | Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. | 1999 | J. Pharmacol. Exp. Ther. | pmid:10215647 |
| Morrow JD et al. | Increased formation of thromboxane in vivo in humans with mastocytosis. | 1999 | J. Invest. Dermatol. | pmid:10417625 |
| Mills JL et al. | Prostacyclin and thromboxane changes predating clinical onset of preeclampsia: a multicenter prospective study. | 1999 | JAMA | pmid:10432033 |
| Barden AE et al. | Does a predisposition to the metabolic syndrome sensitize women to develop pre-eclampsia? | 1999 | J. Hypertens. | pmid:10489109 |
| Mizugaki M et al. | Monitoring of the thromboxane A2/prostacyclin ratio in the urine of patients with retinal vascular occlusion through the low-dose-aspirin therapy using the gas chromatography/selected ion monitoring method. | 1999 | Prostaglandins Other Lipid Mediat. | pmid:10593167 |
| Hishinuma T et al. | Urinary thromboxane A2/prostacyclin balance reflects the pathological state of a diabetic. | 1999 | Prostaglandins Other Lipid Mediat. | pmid:10593168 |
| Hoch B and Bernhard M | Reduced prostacyclin to thromboxane A2 ratio is correlated with central apneas in preterm infants. | 1999 | Prostaglandins Other Lipid Mediat. | pmid:10593170 |
| Arvola P et al. | Exercise enhances vasorelaxation in experimental obesity associated hypertension. | 1999 | Cardiovasc. Res. | pmid:10615427 |
| Tanaka H et al. | Can urinary eicosanoids be a potential predictive marker of clinical response to thromboxane A2 receptor antagonist in asthmatic patients? | 1999 | Respir Med | pmid:10653051 |